A cut above the rest: targeted genome editing technologies in human pluripotent stem cells.
about
Increased Understanding of Stem Cell Behavior in Neurodegenerative and Neuromuscular Disorders by Use of Noninvasive Cell ImagingModeling Kidney Disease with iPS CellsUnderstanding platelet generation from megakaryocytes: implications for in vitro-derived plateletsHow to make an oligodendrocyteCanine Pluripotent Stem Cells: Are They Ready for Clinical Applications?Synthetic biology and therapeutic strategies for the degenerating brain: Synthetic biology approaches can transform classical cell and gene therapies, to provide new cures for neurodegenerative diseasesConcise review: making and using clinically compliant pluripotent stem cell linesTranscriptional regulation of GAD1 GABA synthesis gene in the prefrontal cortex of subjects with schizophreniaConcise review: Generation of neurons from somatic cells of healthy individuals and neurological patients through induced pluripotency or direct conversionInduced pluripotent stem cells in hematology: current and future applicationsModeling diseases of noncoding unstable repeat expansions using mutant pluripotent stem cells.Induced Pluripotent Stem Cell Models to Enable In Vitro Models for Screening in the Central Nervous SystemBMS-708163 and Nilotinib restore synaptic dysfunction in human embryonic stem cell-derived Alzheimer's disease modelsUsher syndrome: Hearing loss, retinal degeneration and associated abnormalities.Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth DiseaseTargeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones.An efficient genotyping method for genome-modified animals and human cells generated with CRISPR/Cas9 system.Improving the safety of cell therapy products by suicide gene transferState-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications.Stem cell therapy. Use of differentiated pluripotent stem cells as replacement therapy for treating disease.CRISPR/Cas9 and TALE: beyond cut and paste.Regenerative medicine: targeted genome editing in vivo.Prospects for In Vitro Myofilament Maturation in Stem Cell-Derived Cardiac Myocytes.Opportunities and Limitations of Modelling Alzheimer's Disease with Induced Pluripotent Stem CellsDestruction of a distal hypoxia response element abolishes trans-activation of the PAG1 gene mediated by HIF-independent chromatin looping.Efficient Recombinase-Mediated Cassette Exchange in hPSCs to Study the Hepatocyte Lineage Reveals AAVS1 Locus-Mediated Transgene InhibitionThe Use of Induced Pluripotent Stem Cells for the Study and Treatment of Liver Diseases.Genome Editing of the CYP1A1 Locus in iPSCs as a Platform to Map AHR Expression throughout Human Development.Synergizing Engineering and Biology to Treat and Model Skeletal Muscle Injury and Disease.Stem and Progenitor Cell-Based Therapy of the Central Nervous System: Hopes, Hype, and Wishful Thinking.Concise Review: Stem Cell-Based Treatment of Pelizaeus-Merzbacher Disease.Glial progenitor cell-based treatment of the childhood leukodystrophies.Human induced-pluripotent stem cell-derived hepatocyte-like cells as an in vitro model of human hepatitis B virus infection.Werner Syndrome-specific induced pluripotent stem cells: recovery of telomere function by reprogrammingCRISPR-Cas9: a new and promising player in gene therapy.The use of stem cells to study autism spectrum disorderRegeneration through reprogramming adult cell identity in vivo.Generating patient-specific induced pluripotent stem cells-derived cardiomyocytes for the treatment of cardiac diseases.Direct somatic lineage conversion.Gene Targeting in Neuroendocrinology.
P2860
Q26753150-D0136C50-7B2A-4B46-8B8F-EFD7C2518054Q26770384-C866B387-79D3-4B03-9817-7D0ECA71BD38Q26770860-56C9FA6F-94B3-4FA9-8BE1-C130FEF7D7BFQ26775534-2D6F5B75-5D27-4AC8-B8C6-789E0FA72E18Q26776075-BFDD7711-31A6-448E-979C-0533346EF098Q26830610-74DD9029-338F-4086-AD56-997A59B7CF06Q26852128-0588613C-41EF-410E-B4E4-08EFCDAEEBFFQ26991794-8D2A978D-EED7-46C4-8805-4A64D772BFE8Q27004350-E1705B5E-A3B4-4100-A3ED-455C8A726DD9Q27016090-FD80A7AA-B724-4572-840B-16CB7201B3C4Q27687330-0B84CB0E-D51C-4BF3-8222-A6A7754BAC14Q28082668-929E5D53-52CC-4A8C-ADEE-993E90D3D867Q28829902-3D256863-9260-49E4-BF4E-882FF5FADD29Q30389509-997101D6-D3A8-47F2-8FA6-D934B7AD3303Q33586017-82F4710B-A12C-4EB3-9B42-A866337C72FFQ34088395-C90DCFD4-54B9-4024-93A9-7279A2EDB05FQ34208869-D5A3E2B7-ED50-4B7D-9CB5-22CF4307817BQ34453846-29A26E37-E967-4162-8727-3DBF1BF2B484Q34664690-DE7DCC84-3353-462F-8D0C-AC55D6FEABD7Q35087066-B9A597BB-9B23-4021-9FCE-EEE22F049BCAQ35143109-76A9DDB7-7784-4944-A308-5FEBD589D5DFQ35146211-BE5CCA21-439D-469F-8FD7-267FDA51100BQ35724421-99CCD434-7D69-450D-B59C-06BFEA488F7AQ35750557-2909E73A-500D-4A7D-974E-1CCA6AD00B43Q35842498-68EA3F85-D4A0-461C-87DE-F904BDC2CD86Q36290454-2C7630D0-BFCD-4FF2-8132-2653B6064966Q36695546-B5F61CE8-7F0D-480B-B7DD-E32477A244D0Q36829190-942D9B8B-B55F-422A-BB39-58BB258A372FQ36874154-D5A43E52-F723-49ED-A5C0-61B0ED8DFD30Q37643268-60279EF3-EA94-4EA4-9B25-A5C3F153F467Q37649702-360193C1-3150-47A6-8861-F7FD5C447E68Q37684345-019FF25A-B588-4979-9C62-8588D19F9970Q37736696-95653C19-2443-432B-9768-FC8190730C61Q38358089-5E39B134-5E2D-49A0-920F-4A42B444FCFDQ38364993-76BFC238-E726-42BC-8597-00F37E47E422Q38368547-4039B7CD-F29D-48C7-AFA9-C3DC162C16B1Q38521894-C6B7255D-8A31-4669-A9C6-5C06311A1E87Q38541742-631294A5-3CF2-430A-83C8-E30E0110D8FAQ38594907-0F050076-3502-4E4E-84F0-51A86479DE54Q38596690-644D1BA1-388B-45BC-9AC4-0E35B36CBE82
P2860
A cut above the rest: targeted genome editing technologies in human pluripotent stem cells.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A cut above the rest: targeted ...... human pluripotent stem cells.
@en
A cut above the rest: targeted ...... human pluripotent stem cells.
@nl
type
label
A cut above the rest: targeted ...... human pluripotent stem cells.
@en
A cut above the rest: targeted ...... human pluripotent stem cells.
@nl
prefLabel
A cut above the rest: targeted ...... human pluripotent stem cells.
@en
A cut above the rest: targeted ...... human pluripotent stem cells.
@nl
P2093
P2860
P356
P1476
A cut above the rest: targeted ...... human pluripotent stem cells.
@en
P2093
Guang-Hui Liu
Keiichiro Suzuki
Na Young Kim
P2860
P304
P356
10.1074/JBC.R113.488247
P407
P577
2013-12-20T00:00:00Z